Who are DBPR108; Placebo matching sitagliptin's main competitors?

No direct comparators detected in our index.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/dbpr108-placebo-matching-sitagliptin.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

DBPR108; Placebo matching sitagliptin — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

DBPR108; Placebo matching sitagliptin (DBPR108; Placebo matching sitagliptin) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: DPP-4 inhibitor (sitagliptin reference). Area: Diabetes.

phase 3 DPP-4 inhibitor (sitagliptin reference) DPP-4 (dipeptidyl peptidase-4) Diabetes Small molecule Live · refreshed every 30 min

Target snapshot

DBPR108; Placebo matching sitagliptin (DBPR108; Placebo matching sitagliptin) — CSPC ZhongQi Pharmaceutical Technology Co., Ltd.. DBPR108 is a placebo matching formulation designed to match sitagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor that increases incretin levels to stimulate insulin secretion in response to glucose.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
DBPR108; Placebo matching sitagliptin TARGET	DBPR108; Placebo matching sitagliptin	CSPC ZhongQi Pharmaceutical Technology Co., Ltd.	phase 3	DPP-4 inhibitor (sitagliptin reference)	DPP-4 (dipeptidyl peptidase-4)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (DPP-4 inhibitor (sitagliptin reference) class)

CSPC ZhongQi Pharmaceutical Technology Co., Ltd. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). DBPR108; Placebo matching sitagliptin — Competitive Intelligence Brief. https://druglandscape.com/ci/dbpr108-placebo-matching-sitagliptin. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab